Cargando…
Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing
Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers are NSCLC and about 16% are SCLC. For the past few years, there have been a lot of new advances in the management of NSCLC in te...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051080/ https://www.ncbi.nlm.nih.gov/pubmed/36986550 http://dx.doi.org/10.3390/ph16030451 |
_version_ | 1785014787938189312 |
---|---|
author | Rajasegaran, Thiviyadarshini How, Chee Wun Saud, Anoosha Ali, Azhar Lim, Jonathan Chee Woei |
author_facet | Rajasegaran, Thiviyadarshini How, Chee Wun Saud, Anoosha Ali, Azhar Lim, Jonathan Chee Woei |
author_sort | Rajasegaran, Thiviyadarshini |
collection | PubMed |
description | Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers are NSCLC and about 16% are SCLC. For the past few years, there have been a lot of new advances in the management of NSCLC in terms of screening, diagnosis and treatment. Unfortunately, most of the NSCLCs are resistant to current treatments and eventually progress to advanced stages. In this perspective, we discuss some of the drugs that can be repurposed to specifically target the inflammatory pathway of NSCLC utilizing its well-defined inflammatory tumor microenvironment. Continuous inflammatory conditions are responsible to induce DNA damage and enhance cell division rate in lung tissues. There are existing anti-inflammatory drugs which were found suitable for repurposing in non-small cell lung carcinoma (NSCLC) treatment and drug modification for delivery via inhalation. Repurposing anti-inflammatory drugs and their delivery through the airway is a promising strategy to treat NSCLC. In this review, suitable drug candidates that can be repurposed to treat inflammation-mediated NSCLC will be comprehensively discussed together with their administration via inhalation from physico-chemical and nanocarrier perspectives. |
format | Online Article Text |
id | pubmed-10051080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100510802023-03-30 Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing Rajasegaran, Thiviyadarshini How, Chee Wun Saud, Anoosha Ali, Azhar Lim, Jonathan Chee Woei Pharmaceuticals (Basel) Review Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers are NSCLC and about 16% are SCLC. For the past few years, there have been a lot of new advances in the management of NSCLC in terms of screening, diagnosis and treatment. Unfortunately, most of the NSCLCs are resistant to current treatments and eventually progress to advanced stages. In this perspective, we discuss some of the drugs that can be repurposed to specifically target the inflammatory pathway of NSCLC utilizing its well-defined inflammatory tumor microenvironment. Continuous inflammatory conditions are responsible to induce DNA damage and enhance cell division rate in lung tissues. There are existing anti-inflammatory drugs which were found suitable for repurposing in non-small cell lung carcinoma (NSCLC) treatment and drug modification for delivery via inhalation. Repurposing anti-inflammatory drugs and their delivery through the airway is a promising strategy to treat NSCLC. In this review, suitable drug candidates that can be repurposed to treat inflammation-mediated NSCLC will be comprehensively discussed together with their administration via inhalation from physico-chemical and nanocarrier perspectives. MDPI 2023-03-16 /pmc/articles/PMC10051080/ /pubmed/36986550 http://dx.doi.org/10.3390/ph16030451 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rajasegaran, Thiviyadarshini How, Chee Wun Saud, Anoosha Ali, Azhar Lim, Jonathan Chee Woei Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing |
title | Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing |
title_full | Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing |
title_fullStr | Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing |
title_full_unstemmed | Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing |
title_short | Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing |
title_sort | targeting inflammation in non-small cell lung cancer through drug repurposing |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051080/ https://www.ncbi.nlm.nih.gov/pubmed/36986550 http://dx.doi.org/10.3390/ph16030451 |
work_keys_str_mv | AT rajasegaranthiviyadarshini targetinginflammationinnonsmallcelllungcancerthroughdrugrepurposing AT howcheewun targetinginflammationinnonsmallcelllungcancerthroughdrugrepurposing AT saudanoosha targetinginflammationinnonsmallcelllungcancerthroughdrugrepurposing AT aliazhar targetinginflammationinnonsmallcelllungcancerthroughdrugrepurposing AT limjonathancheewoei targetinginflammationinnonsmallcelllungcancerthroughdrugrepurposing |